Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)

BMC Cancer. 2015 Nov 6;15:857. doi: 10.1186/s12885-015-1881-x.

Abstract

Background: Malignant pleural mesothelioma (MPM) is a rare disease with poor prognosis in spite of significant improvement in survival, due to new chemotherapy regimens. We describe here patients' profiles and management in daily practice in France.

Methods: Observational retrospective study. Data were collected from medical files. All patients with histologically proven MPM diagnosed from January 2005 to December 2008 were included in the participating sites.

Results: Four hundred and six patients were included in 37 sites: mean age 68.9 ± 9.8 years, male predominance (sex ratio 3.27), latency of the disease 45.7 years, epithelioïd type 83 %. Diagnosis was made using thoracoscopy in 80.8 % of patients. Radical surgery was performed in 6.2 % of cases. Chemotherapy was administered to 74.6 % of patients. First line regimens consisted mainly of platinum + pemetrexed (91 %) or pemetrexed alone (7 %). Objective response rate was 17.2 % and another 41.6 % of patients experienced disease stabilization. Half of these patients underwent second line chemotherapy (platinium + pemetrexed 31.6 %, pemetrexed alone 24.6 %), resulting in a 6 % response rate. Third-line chemotherapy (56 patients) yielded disease control in 5.4 % of cases.

Conclusions: The management of MPM in France is usually in accordance with guidelines. Response rates are somewhat lower than those described in clinical trials.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Disease Management
  • Female
  • France / epidemiology
  • Humans
  • Lung Neoplasms / diagnosis*
  • Lung Neoplasms / epidemiology
  • Lung Neoplasms / therapy*
  • Male
  • Mesothelioma / diagnosis*
  • Mesothelioma / epidemiology
  • Mesothelioma / therapy*
  • Mesothelioma, Malignant
  • Middle Aged
  • Outcome Assessment, Health Care
  • Pleural Neoplasms / diagnosis*
  • Pleural Neoplasms / epidemiology
  • Pleural Neoplasms / therapy*
  • Retrospective Studies
  • Risk Factors